London, UK – Belluscura, a leading developer of medical devices, has recently announced a groundbreaking partnership with InnoMax Medical Technology, a prominent Chinese company. Under this exclusive 10-year agreement, Belluscura will have the opportunity to manufacture and distribute its innovative portable oxygen concentrators across China, Hong Kong, Macau, and Singapore.
As part of the agreement, Belluscura will receive annual royalties on licensed products and a share of the net profits from accessories sales. The deal also includes a provision for a nonexclusive license if minimum sales targets are not met after the initial five-year exclusive period.
Valued at an impressive $27.5 million to $55 million over the term of the license, this collaboration marks a significant milestone for both companies.
Belluscura’s X-Plor device and its ambulatory dual-flow portable oxygen concentrator Discov-R will be covered under this agreement. The registration process for both devices is currently underway, with the first sales expected to commence in the fourth quarter.
This strategic partnership not only expands Belluscura’s global reach but also underscores its commitment to providing innovative devices that enhance the quality of life for patients in need of respiratory support.
